Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles

Hwang, Ho Young; Kim, In San; Kwon, Ick Chan; Kim, Yong Hee

doi:10.1016/j.jconrel.2008.02.003

Cited by 239 publications

(161 citation statements)

References 22 publications

Supporting

Mentioning

157

Contrasting

Order By: Relevance

“…The total RNA used was the same as that used in the microarray assay and purified with RNeasy Plus Mini Kit (Qiagen NV, Venlo, the Netherlands). Purified RNA was reverse transcribed into complementary DNA by using an Oligo(dT) 15 Primer (Promega Corporation, Fitchburg, WI, USA) and M-MLV Reverse Transcriptase (Promega) following the manufacturer's instructions. The qPCR was performed with iQ SYBR ® Green Supermix (Bio-Rad) with standard protocol.…”

Section: Quantitative Polymerase Chain Reaction (Qpcr)mentioning

confidence: 99%

Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity

Yuan¹,

Han²,

Cong³

et al. 2014

IJN

View full text Add to dashboard Cite

Docetaxel is an adjuvant chemotherapy drug widely used to treat multiple solid tumors; however, its toxicity and side effects limit its clinical efficacy. Herein, docetaxel-loaded solid lipid nanoparticles (DSNs) were developed to reduce systemic toxicity of docetaxel while still keeping its anticancer activity. To evaluate its anticancer activity and toxicity, and to understand the molecular mechanisms of DSNs, different cellular, molecular, and whole genome transcription analysis approaches were utilized. The DSNs showed lower cytotoxicity compared with the commercial formulation of docetaxel (Taxotere ® ) and induced more apoptosis at 24 hours after treatment in vitro. DSNs can cause the treated cancer cells to arrest in the G2/M phase in a dose-dependent manner similar to Taxotere. They can also suppress tumor growth very effectively in a mice model with human xenograft breast cancer. Systemic analysis of gene expression profiles by microarray and subsequent verification experiments suggested that both DSNs and Taxotere regulate gene expression and gene function, including DNA replication, DNA damage response, cell proliferation, apoptosis, and cell cycle regulation. Some of these genes expressed differentially at the protein level although their messenger RNA expression level was similar under Taxotere and DSN treatment. Moreover, DSNs improved the main side effect of Taxotere by greatly lowering myelosuppression toxicity to bone marrow cells from mice. Taken together, these results expound the antitumor efficacy and the potential working mechanisms of DSNs in its anticancer activity and toxicity, which provide a theoretical foundation to develop and apply a more efficient docetaxel formulation to treat cancer patients.

show abstract

Section: Quantitative Polymerase Chain Reaction (Qpcr)mentioning

confidence: 99%

Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity

Yuan¹,

Han²,

Cong³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…[16][17][18][19][20][21][22][23][24][25] FRI is generally considered to be an excellent tool for monitoring nanomedicine accumulation in superficial tissues, such as subcutaneously inoculated tumors, but it is unable to provide quantitative information, and it also does not allow for the assessment of nanomedicine accumulation in deeper-seated tissues. 26 This means that it can be used for qualitative and comparative analyses, in which e.g.…”

mentioning

confidence: 99%

Noninvasive Optical Imaging of Nanomedicine Biodistribution

et al. 2012

View full text Add to dashboard Cite

Nanomedicines are submicrometer-sized carrier materials designed to improve the biodistribution of i.v. administered (chemo-) therapeutic agents. In recent years, ever more efforts in the nanomedicine field have employed optical imaging (OI) techniques to monitor biodistribution and target site accumulation. Thus far, however, the longitudinal assessment of nanomedicine biodistribution using OI has been impossible, due to limited light penetration (in case of 2D fluorescence reflectance imaging; FRI), and to the inability to accurately allocate fluorescent signals to non-superficial organs (in case of 3D fluorescence molecular tomography; FMT). Using a combination of high-resolution micro-computed tomography (μCT) and FMT, we have here set out to establish a hybrid imaging protocol for non-invasively visualizing and quantifying the accumulation of near-infrared fluorophore-labeled nanomedicines in tissues other than superficial tumors. To this end, HPMA-based polymeric drug carriers were labeled with Dy750, their biodistribution and tumor accumulation were analyzed using FMT, and the resulting data sets were fused with anatomical μCT data sets in which several different physiologically relevant organs were pre-segmented. The robustness of 3D organ segmentation was validated, and the results obtained using 3D CT-FMT were compared to those obtained upon standard 3D FMT and 2D FRI. Our findings convincingly demonstrate that combining anatomical μCT with molecular FMT facilitates the non-invasive assessment of nanomedicine biodistribution. KeywordsNanomedicine; Drug targeting; Biodistribution; FMT; FRI; CT Nanomedicines aim to deliver drugs and imaging agents more efficiently and more specifically to pathological sites. A significant amount of evidence has been obtained over the years exemplifying the superiority of nanomedicine formulations over free drugs, both at the preclinical and at the clinical level. [1][2][3][4][5] Prototypic examples of nanomedicine formulations are liposomes, polymers, micelles and nanoparticles. These submicrometersized carrier materials are designed to modulate the pharmacokinetics and the biodistribution of conjugated or entrapped (chemo-) therapeutic drugs. Upon intravenous (i.v.)

show abstract

“…NPs used for such matters are mostly designed to be drug-compatible, biocompatible, biodegradable, and easy to process, efficient in loading and controlling drug release [125]. In addition, modern developments in polymeric nano-formulations involve a number of homo and co-polymer combinations pertaining for sustained and controlled delivery of anti-cancer agents [126][127][128][129][130][131].…”

Section: Development Efforts On Camel Products Based Anticancer Nanopmentioning

confidence: 99%

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Alebie¹,

Yohannes²,

Worku³

2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles

Cited by 239 publications

References 22 publications

Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity

Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity

Noninvasive Optical Imaging of Nanomedicine Biodistribution

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Contact Info

Product

Resources

About